AEROVATE THERAPEUTICS INC

AVTE05 Dec 2024
Healthcare
$2.63
-0.03 (-2.67%)
Lowest Today
$2.54
Highest Today
$2.63
Today’s Open
$2.63
Prev. Close
$2.62
52 Week High
$32.42
52 Week Low
$1.25
To Invest in AEROVATE THERAPEUTICS INC

AEROVATE THERAPEUTICS INC

Healthcare
AVTE05 Dec 2024
-0.03 (-2.67%)
1M
3M
6M
1Y
5Y
Low
$2.54
Day’s Range
High
$2.62
2.54
52 Week Low
$1.25
52-Week Range
52 Week High
$32.42
1.25
1 Day
-
1 Week
-1.13%
1 month return
-3.67%
3 month return
+38.62%
6 month return
-83.94%
1 Year return
-84.09%
3 Years return
-77.56%
5 Years return
-
10 Years return
-
Institutional Holdings
RA Capital Management, LLC
31.83
Sofinnova Ventures
13.02
TCG Crossover Management, LLC
7.76
Deerfield Management Co
4.89
Vanguard Group Inc
3.99
BlackRock Inc
3.4
Baker Bros Advisors LP
2.18

Market Status

Fundamentals
Market Cap
76.81 mln
PB Ratio
0.95
PE Ratio
0
Enterprise Value
-11.38 mln
Total Assets
127.42 mln
Volume

Company Financials

Fund house & investment objective

Company Information
Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. The company was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
Organisation
AEROVATE THERAPEUTICS INC
Employees
51
Industry
Biotechnology
CEO
Mr. Timothy P. Noyes M.B.A.
Trading and brokerage services provided by
Technology Services provided by Motilal Oswal Financial Services:

Take your next step